Gao takes chair from Chan at China Biologic
This article was originally published in Scrip
David (Xiaoying) Gao has been elected chairman of the board of directors at China Biologic Products, taking over from Siu Ling Chan who served for more than five years, and who will remain on the board. Mr Gao’s appointment comes as the board adopts a series of measures to improve the company’s corporate governance, enhancing the independence and transparency of the board. These include increasing the size of the board from seven to nine members, with the intention of appointing two new independent directors. Mr Gao joined the board of directors in October 2011. China Biologic operates through subsidiaries in China as a major plasma-based biopharmaceutical company in that market. Mr Gao was previously CEO and director of BMP Sunstone, which was acquired by Sanofi last year. He was also chairman of Beijing Med-Pharm from 2002 to 2004. The company has also appointed Ming Yang as vice-president, finance and compliance and treasurer.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.